TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

• Main Authors: Eleonora Ghisoni (Author), Furio Maggiorotto (Author), Fulvio Borella (Author), Gloria Mittica (Author), Sofia Genta (Author), Gaia Giannone (Author), Dionyssios Katsaros (Author), Alberto Sciarrillo (Author), Annamaria Ferrero (Author), Ivana Sarotto (Author), Jessica Erriquez (Author), Maria Flavia Di Renzo (Author), Massimo Aglietta (Author), Giorgio Valabrega (Author)
• Format: Book
• Published: BMC, 2019-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Objective Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD). Unfortunately, most patients do not benefit from treatment. Prediction of response is crucial to optimize PLD use and avoid unnecessary toxicities. We aimed at assessing the...